肾硬化症慢性肾脏病进展的临床病理预测因素:基于活检的队列研究
本研究回顾性纳入401例日本活检确诊肾硬化症患者,中位随访5.3年,117例出现CKD进展。多变量竞争风险模型显示低白蛋白、低HbA1c、低eGFR、高UACR、高节段/全球肾小球硬化百分比及IFTA为CKD进展风险因素,病理信息可提升预测效能。
要点
- 低血清白蛋白、低HbA1c、低eGFR、高UACR与CKD进展独立相关
- 肾小球硬化百分比和IFTA是独立病理预测因素
- 活检病理信息(尤其IFTA)可改善CKD进展预测模型
核心结论
- 除传统eGFR和UACR外,血清白蛋白、HbA1c及活检间质损伤程度有助于预测肾硬化症患者CKD进展。
研究设计与样本
- 回顾性队列研究,纳入日本401例活检确诊肾硬化症患者,中位随访5.3年。
主要发现
- 随访期间117例CKD进展,10例在肾脏事件前死亡。
- 多变量竞争风险模型显示血清白蛋白SHR 0.48(95%CI 0.35-0.67)、HbA1c SHR 0.71(95%CI 0.54-0.94)、eGFR SHR 0.98(95%CI 0.97-0.99)、UACR SHR 1.18(95%CI 1.08-1.29)、%GS SHR 1.01(95%CI 1.00-1.02)、IFTA SHR 1.52(95%CI 1.20-1.92)为CKD进展风险因素。
- 仅临床变量模型C统计量0.790,加入%GS升至0.796(P<0.01),加入IFTA升至0.811(P<0.01)。
- 加入活检数据后重分类统计量改善,含IFTA模型AIC最低。
临床怎么用
- 对肾硬化症患者应关注血清白蛋白和HbA1c,并考虑活检评估间质损伤程度以优化CKD进展风险分层。
局限性
- 回顾性单中心日本队列,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biopsy-based studies on nephrosclerosis are lacking and the clinicopathological predictors for progression of chronic kidney disease (CKD) are not well established. METHODS: We retrospectively assessed 401 patients with biopsy-proven nephrosclerosis in Japan. Progression of CKD was defined as new-onset end-stage renal disease, decrease of estimated glomerular filtration rate (eGFR) by ≥50% or doubling of serum creatinine, and the sub-distribution hazard ratio (SHR) with 95% confidence interval (CI) for CKD progression was determined for various clinical and histological characteristics in competing risks analysis. The incremental value of pathological information for predicting CKD progression was assessed by calculating Harrell's C-statistics, the Akaike information criterion (AIC), net reclassification improvement and integrated discrimination improvement. RESULTS: During a median follow-up period of 5.3 years, 117 patients showed progression of CKD and 10 patients died before the defined kidney event. Multivariable sub-distribution hazards model identified serum albumin (SHR 0.48; 95% CI 0.35-0.67), hemoglobin A1c (SHR 0.71; 95% CI 0.54-0.94), eGFR (SHR 0.98; 95% CI 0.97-0.99), urinary albumin/creatinine ratio (UACR) (SHR 1.18; 95% CI 1.08-1.29), percentage of segmental/global glomerulosclerosis (%GS) (SHR 1.01; 95% CI 1.00-1.02) and interstitial fibrosis and tubular atrophy (IFTA) (SHR 1.52; 95% CI 1.20-1.92) as risk factors for CKD progression. The C-statistic of a model with only clinical variables was improved by adding %GS (0.790 versus 0.796, P < 0.01) and IFTA (0.790 versus 0.811, P < 0.01). The reclassification statistic was also improved after adding the biopsy data to the clinical data. The model including IFTA was superior, with the lowest AIC. CONCLUSIONS: The study implies that in addition to the traditional markers of eGFR and UACR, we may explore the markers of serum albumin and hemoglobin A1c, which are widely available but not routinely measured in patients with nephrosclerosis, and the biopsy data, especially the data on the severity of interstitial damage, for the better prediction of CKD progression in patients with nephrosclerosis.
引用
- Yamanouchi M, Hoshino J, Ubara Y, et al. Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. Nephrol Dial Transplant. 2019. PMID: 29788462. doi:10.1093/ndt/gfy121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。